Oestradiol-17β plasma concentrations after intramuscular injection of oestradiol benzoate or oestradiol cypionate in llamas (Lama glama)

María V Cavilla*, Carolina P Bianchi, Marcelo A Aba

Abstract

**Background**: Llamas (Lama glama) are induced ovulators and the process of ovulation depends on dominant follicular size. In addition, a close relationship between behavioural estrus and ovulation is not registered in llamas. Therefore, the exogenous control of follicular development with hormones aims to predict the optimal time to mate. Oestradiol-17β (E2) and its esters are currently used in domestic species, including camelds, in synchronization treatments. But, in llamas, there is no reports regarding the appropriate dosages to be used and most protocols have been designed by extrapolation from those recommended for other ruminants. The aim of the present study was to characterize plasma E2 concentrations in intact female llamas following a single intramuscular (i.m.) injection of two oestradiol esters: oestradiol benzoate (EB) and oestradiol cypionate (ECP).

**Methods**: Twelve non pregnant and non lactating sexually mature llamas were i.m. injected on day 0 with 2.5 mg of EB (EB group, n = 6) or ECP (ECP group, n = 6). Blood samples were collected immediately before injection, at 1, 6, 12, 24 h after treatment and then daily until day 14 post injection. Changes in hormone concentrations with time were analyzed in each group by analysis of variance (ANOVA) using a repeated measures (within-SS) design. Plasma E2 concentrations and area under the concentration-time curve (AUC) values were compared between groups by ANOVA. In all cases a Least-Significant Difference test (LSD) was used to determine differences between means. Hormonal and AUC data are expressed as mean ± S.E.M.

**Results**: Peak plasma E2 concentrations were achieved earlier and were higher in EB group than in ECP group. Thereafter, E2 returned to physiological concentrations earlier in EB group (day 5) than in ECP group (day 9). Although plasma E2 profiles differed over time among groups there were no differences between them on AUC values.

**Conclusions**: The i.m. injection of a single dose of both oestradiol esters resulted in plasma E2 concentrations exceeding physiological values for a variable period. Moreover, the plasma E2 profiles observed depended on the derivative of oestradiol administered. This basic information becomes relevant at defining treatment protocols including oestrogens in llamas.

**Background**

Llamas (Lama glama) are ruminants with physiological peculiarities, particularly regarding their reproductive physiology. Ovarian follicles develop in a wave-like pattern as in other ruminants: cows [1]; ewes [2]; goats [3], but the process of ovulation requires the stimulus of mating and ejaculation [4-8]. Moreover, only growing, dominant follicles ≥ 7 mm in diameter present at the time of mating have the ability to ovulate [9]. In the absence of ovulation, successive waves of follicular growth and regression that generally overlap, proceed [10,11]. The oestrogens produced during those waves determine long periods of receptivity (≥ 30 days), interrupted by short stages of male rejection [4,12]. Thus, a set of signals indicative of the presence of a mature follicle is not registered in the llama [5,6,11]. Furthermore, the female might accept the male in the absence of a qualified follicle resulting in ovulation failure. Therefore,
the control of follicular development with exogenous hormones assuring the presence of a healthy mature follicle at a fixed time after treatment would enable the implementation of reproductive technologies leading to an increase in productivity.

Oestrogens are a family of steroid hormones involved in female reproductive processes regulating and sustaining sexual development and reproductive function. Oestradiol-17β (E₂) is the most abundant and active of the endogenous oestrogens produced by the ovary [13]. In addition, oestradiol esters are a group of synthetic oestrogens that includes: oestradiol benzoate (EB), oestradiol valerate (EV) and oestradiol cypionate (ECP). Oestradiol-17β and EB are commonly used to induce follicular regression and to synchronize wave emergence and ovulation in progesterin-treated cattle [14-17]. The inclusion of ECP in hormonal regimens has increased in recent years as in some countries is the only ester available and licensed for use in cattle, but its success to hasten wave emergence has been relatively variable to date [18,19].

The time to wave emergence after E₂ treatment in cattle, appears to depend on the dose and formulation administered. It appears that the greater the circulating concentrations of E₂, or the time to return to physiological range, the greater are follicular and FSH suppression [16,20-22]. Thus the use of an “optimal” dose or formulation of E₂ in hormonal regimens is emphasized by the previous observations. Conversely, in camelids information regarding the effects of oestrogens on follicular activity is scanty and controversial [23-26]. In addition, there is no reports regarding the appropriate dosages to be used in llamas and most protocols have been designed by extrapolation from those recommended for other ruminants. While establishing those dose regimens, it has never been considered that camelids show pharmacological differences for the metabolism of several drugs as compared to other ruminants [27-30].

The study hereby reported, was designed to provide a comparative characterization of plasma E₂ concentrations following a single i.m. injection of two oestradiol esters (EB and ECP). This information would provide basic knowledge useful for a more rational use of these drugs in the species.

**Methods**

**Animals and treatments**

The experimental design and animal care were performed in compliance with regulations set by the Animal Welfare Committee at the Faculty of Veterinary Sciences, UNCPBA, Tandil, Argentina (37°S, 60°W) where activities were carried out. Animals were kept isolated from males and fed pasture hay and had free access to water during the entire experimental period. Twelve sexually mature, non pregnant and non lactating female llamas (107.5 ± 17.68 Kg) were randomly divided into two treatment groups: EB (n = 6) and ECP (n = 6). On day 0 all animals received a single i.m. injection (0 h) of 2.5 mg of oestradiol benzoate (EB, Benzoato de Estradiol Syntex®, Syntex SA, Buenos Aires, Argentina) or oestradiol cypionate (ECP, ecp estradiol®, König, Buenos Aires, Argentina) into the hind leg in the region of the semitendinosus muscle. The dose of EB was selected based on previous studies in llamas and alpacas [24,31]. In general, a larger dose of EB has been used in cameld as compared to that used in synchronization programs in cattle [15,24,26,31], probably in relation to a higher metabolic rate reported in camelds for different drugs [27-30]. In addition, to allow a direct comparison between esters and due to the lack of reports using ECP in the specie the same dose was used for ECP.

**Blood sampling**

Blood samples were collected into heparinized tubes immediately before injection, at 1, 6, 12, 24 h after treatment, and then daily until day 14 post injection. In order to minimize damage to the jugular veins due to the high frequency sampling protocol, venipuncture was performed alternately at high, medium and low positions on the left and right sides of the neck as previously described by Aba et al. [32]. Plasma samples were separated by centrifugation and stored at -20°C until analyzed.

**Hormone determinations**

Oestradiol-17β plasma concentrations were measured using an RIA Kit (Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA) reported for use with bovine plasma [33], and validated for use with llama plasma after minor modifications [6]. Plasma and standards were previously extracted using diethyl ether (Merck, Buenos Aires, Argentina). The intra-assay coefficient of variation was below 10% for concentrations between 5.6 and 180 pmol l⁻¹. The inter-assay coefficient of variation, calculated from the precision profiles of five standard curves, was below 6% for concentrations between 5.6 and 180 pmol l⁻¹. The lowest amount of E₂ detectable was 5.6 pmol l⁻¹. Plasma progesterone (P₄) concentrations were measured using an RIA Kit (Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA) previously validated for use with llama plasma [34]. The sensitivity of the assay was 0.3 nmol l⁻¹ and the intra-assay coefficient of variation was below 13% for concentrations between 0.4 and 128 nmol l⁻¹. All samples were measured in duplicates. Hormone concentrations are expressed in SI units. To convert from pmol l⁻¹ to pg ml⁻¹ and from nmol l⁻¹ to ng ml⁻¹, a factor of 3.7 for oestradiol-17β and 3.2 for progesterone should be used.
Analysis of data

In order to establish a physiological plasma E2 concentration upper limit before treatment, twice the standard deviation (SD) was added to the general mean as previously described by Vynckier et al. [35]. Any concentration above (P < 0.05) this limit was considered pharmacological. Changes in hormone concentrations with time on each treatment group were analyzed by ANOVA using a repeated measures (within-SS) design. Mean E2 concentrations at each time were statistically compared among groups by ANOVA. In all cases, a Fisher’s Least-Significant Difference test (LSD) was used to determine differences between means. Log-transformation was used for plasma E2 concentrations before analyses to stabilize variances. The area under the concentration-time curve (AUC) from time zero to the last measurable concentration was calculated by the trapezoidal rule [36]. The AUC values obtained after the injection of both esters were statistically compared between groups by ANOVA. Statistical analyses were carried out using the Statistica/W, release 4.0 software package (Statsoft Inc., Tulsa, OK, USA, 1993). Statistical significance was set at P < 0.05. Hormonal and AUC data are expressed as mean ± S.E.M unless otherwise specified.

Results

Physiological plasma E2 concentrations

Oestradiol-17β plasma concentrations varied widely between animals at the beginning of the study (ranging from 13.7 to 44.7 pmol l⁻¹). Mean plasma E2 concentration before injection (considering all females) was 33.1 ± 11.7 pmol l⁻¹ (mean ± SD). The physiological upper limit for plasma E2 concentrations was established at 56.5 pmol l⁻¹.

Plasma E2 concentrations and AUC values after oestradiol esters injection

The administration of both formulations resulted in plasma E2 concentrations largely exceeding physiological values. Mean plasma E2 concentrations during 14 days after i.m. injection of EB and ECP are shown in Figure 1. In EB group, E2 plasma concentrations increased sharply (P < 0.0001) by 1 h after injection, reaching peak concentrations (484.9 ± 85.6 pmol l⁻¹) by 6 h after injection. Oestradiol-17β plasma concentrations remained elevated until 12 h and then followed a biphasic decline. Firstly, E2 concentrations underwent a sharp decrease between 12 h and day 1, remained relatively stable between days 1 and 2 and steadily decreased onwards returning to physiological values by day 5 post injection. In ECP group, E2 concentrations increased slowly from 6 h after injection (P < 0.0001) until peak concentrations (157.1 ± 8.7 pmol l⁻¹) were reached on day 1. Thereafter, plasma E2 concentrations declined slowly, until concentrations no longer distinguishable from physiological were attained on day 9. Subsequently, plasma E2 concentrations fluctuated close to physiological values until the end of the study.

Although plasma E2 concentrations profiles differ according to treatment, the AUC values obtained following injection were similar between groups (EB: 1336.01 ± 157.4 pmol*day/l; ECP: 1189.78 ± 87.44 pmol*day/l; P = 0.5306). Thus, mean E2 concentrations in EB group were higher than in ECP group at all times beyond the 0 h sample until day 2 with a rapid fell onwards. In contrast, in ECP group mean E2 concentrations experienced a slower increase, but more prolonged in time, attaining values higher than in EB group between day 6 and day 13 inclusive. On days 3 to 5 and on day 14 plasma E2 concentrations were similar among groups. Plasma P₄ concentrations remained bellow 3 nmol l⁻¹ in all females during the entire period of study.

Discussion

Plasma E2 concentrations and its variability between animals recorded before treatment in the present study (range from 13.7 to 44.7 pmol l⁻¹) are consistent with previous reports in llamas [6,37,38]. This observation indicates animals were at different stages of follicular development at the time of treatment, as it has been established a close relationship between follicular activity and E2 secretion in llamas [5,6,38,39]. In addition, the plasma E2 concentration established as the physiological upper limit in the present study was somehow in agreement to that previously registered during the follicular phase (17 to 47 pmol l⁻¹) in llamas [38]. The fact that plasma P₄ concentrations remained bellow 3 nmol l⁻¹ in all cases indicates that no ovulations occurred during the study [6].

To our knowledge, this is the first report showing the plasma E2 profile following a single i.m. injection of ECP and its comparison to the profile obtained after injection of EB in llamas. Treatment with both oestra-diol derivatives induced plasma E2 concentrations exceeding those considered physiological for the species. Moreover, the plasma E2 profiles recorded in the present study clearly depended on the ester administered and were consistent with that registered in cows by Vynckier et al. [35]. Plasma E2 concentrations increased rapidly and peaked earlier in EB group with values three-times higher than in ECP group. Similar results were previously observed after EB injection in bovines [21,22].

Peak plasma E2 concentrations achieved after EB injection in the present study were higher than those recorded before in camelsids [24,31] and were attained earlier than observed by others [24] in alpacas. Although there is no clear explanation for the divergences
biphasic decline of plasma E2 concentrations until phy- the declination rate also differed between esters. The cows by Vynckier in our study is consistent with that recorded in 9 onwards. Although the pattern of decline observed for concentrations fluctuated close to physiological values from day 5 a phase of the curve was shorter and plasma E2 concentra- tions returned to physiological values (P > 0.05). Once peak plasma E2 concentrations were reached, the declination rate also differed between esters. The biphasic decline of plasma E2 concentrations until physiolog- ical values on day 5 in EB group is in agreement with previous reports in alpacas and cows [24,35]. As stated by Vynckier et al. [35] these biphasic decline sug- gest an initial phase of distribution followed by an elimi- nation phase. In contrast, in ECP group, the decreasing phase of the curve was shorter and plasma E2 concentra- tions returned to physiological values (P > 0.05). From the analysis of plasma E2 concentrations, it is apparent that ECP was absorbed at a lower rate than EB, but persisted elevated in plasma for a longer period (8 and 4 days, respectively). Besides the different rates of absorption, the same amount of drug was released from the injection site for both esters, since by the end of the study the AUCs values were similar between groups. These findings are consistent with the fact that the esterification process prolongs the half-life of E2. Appar- ently, the ester injected influences the mode that E2 is released from the injection site. Thus, there is an inverse relationship between the extension of the ester chain and its water solubility and consequently, on its absorp- tion rate. Once in circulation, the esters are hydrolyzed to E2, the active hormone. Consequently, the duration of action appears to depend on the rate of absorption more than the metabolism [40].

It has been suggested in llamas that hormonal treat- ments with progestogens are effective in completely prevent follicular development for a period of up to 7 days with the lowest follicular activity registered between days 5 and 7 after beginning of treatment [32-38]. Thereafter, most attempts to control follicular activity includes short protocols (5 to 7 days) and a combination of a progestogen and oestrogens. According to the results hereby presented, E2 plasma concentrations would remain at pharmacological concentrations beyond the day of progestogen withdrawal after ECP treatment. Conversely, plasma E2 concentrations would have return to physiological values before the end of the synchroniza- tion protocol after EB injection. Whether this might influence the outcome of the synchronization treatment or not remains to be elucidated.

Conclusions
To our knowledge, this is the first study that provides a characterization of the plasma E2 concentrations profile following a single i.m. injection of ECP and a direct comparison to that obtained after EB injection in intact female llamas. Both esters effectively induced pharmacological E2 concentrations, however, plasma E2 profiles depended on the formulation administered. Peak plasma E2 concentrations were higher and were attained earlier after EB injection compared to ECP with an earlier return to physiological values. This basic information becomes relevant at defining treatment protocols including oestrogens in llamas.

Acknowledgements
This study was supported by grants from Agencia Nacional de Promoción Científica y Tecnológica (PICT 08-14231). MVC and CPB are holders of a fellowship from Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET).

Authors' contributions
MVC participated in developing the design of the experiment, carried out the experiment, gathered and analyzed the data, and drafted the manuscript. CPB contributed in carrying out the experiment and with contents of the manuscript. MAA as the director of the doctoral project of MVC designed the experiment, contributed in carrying out the experiment,
with the analysis of the data and revising critically the contents of the manuscript. All authors have read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 15 December 2009
Accepted: 11 February 2010 Published: 11 February 2010

References
1. Ginthier OJ, Kastelic JP, Knofl L: Composition and characteristics of follicular waves during the bovine estrus cycle. Anim Reprod Sci 1989, 20:187-200.
2. Evans AC, Duffy P, Hynes N, Boland MP: Waves of follicle development during the estrous cycle in sheep. Theriogenology 2000, 53:699-715.
3. Rubianes E, Menchaca A: The pattern and manipulation of ovarian follicular growth in goats. Anim Reprod Sci 2000, 78:271-287, (review).
4. San-Martín M, Copería M, Zuñiga J, Rodríguez R, Bustíga G, Acosta L: Aspects of reproduction in the alpaca. J Reprod Fertil 1968, 16:395-399.
5. Bravo PW, Fowler ME, Stabenfeldt GH, Lasley BL: Ovarian follicular dynamics in the llama. Biol Reprod 1990, 43:579-585.
6. Aba MA, Forsberg M, Kindahl H, Sumar J, Edqvist LE: Endocrine changes after mating in pregnant and non-pregnant llamas and alpacas. Acta Vet Scand 1995, 36:489-498.
7. Chen BX, Yuen ZK, Pan GW: Semen-induced ovulation in the Bactrian camel (Camelus bactrianus). J Reprod Fertil 1985, 74:335-339.
8. Adams GP, Ratto MH, Huanca W, Singh J: Effects of ovulatory follicle size on pituitary and ovarian responses to copulation in domesticated South American camelids. Biol Reprod 1991, 45:533-550.
9. Adams GP, Sumar J, Ginthier OJ: Effects of lactational and reproductive status on ovarian follicular waves in llamas (Lama glama). J Reprod Fertil 1990, 90:535-545.
10. Vaughan JL, Tibary A: Reproduction in female South American camels: A review and clinical observations. Small Rumin Res 2006, 61:259-281.
11. England BG, Footic WC, Cardozo AG, Mathews DH, Riera S: Oestrus and mating behaviour in the llama (Lama glama). Anim Behav 1971, 19:722-726.
12. Reeves JJ: Endocrinology of Reproduction. Reproduction in farm animals Philadelphia: Lea & Febiger/Hafiez ESE, Fifth 1987, 85-106.
13. Bo GA, Adams GP, Pierson RA, Tribulo HE, Baccia M, Mapletoft RJ: Follicular wave dynamics after estradiol-17β treatment of heifers with or without a progestogen implant. Theriogenology 1994, 41:1555-1569.
14. Bo GA, Baruselli PS, Moreno D, Cutaia L, Caccia M, Tribulo R, Tribulo HE, Mapletoft RJ: The control of follicular wave development for self-appointed embryo transfer programs in cattle. Theriogenology 2003, 57:53-72, (review).
15. Burke CR, Mussiao ML, Gasser CL, Grum DE, Day ML: Estradiol benzoate delays new follicular wave emergence in a dose-dependent manner after ablation of the dominant ovarian follicle in cattle. Theriogenology 2003, 60:647-658.
16. Martinez MF, Kastelic JP, Bo GA, Caccia M: Mapletoft RJ: Effects of estradiol and some of its esters on gonadotrophin release and ovarian follicular dynamics in CIDR-treated beef cattle. Anim Reprod Sci 2005, 86:37-52.
17. Thundathil J, Kastelic JP, Mapletoft RJ: The effect of estradiol cypionate (ECP) on ovarian follicular development and ovulation in dairy cattle. Can J Vet Res 1997, 61:314-316.
18. Colazo MG, Kastelic JP, Mapletoft RJ: Effects of estradiol cypionate (ECP) on ovarian follicular dynamics, synchrony of ovulation, and fertility in CIDR-based, fixed-time AI programs in beef heifers. Theriogenology 2003, 60:855-865.
19. Bo GA, Bergfelt DR, Brogatti GM, Pierson RA, Adams GP, Mapletoft RJ: Local versus systemic effects of exogenous estradiol-17β on ovarian follicular dynamics in heifers with progestogen implants. Anim Reprod Sci 2000, 59:141-157.
20. O’Rourke M, Diskin MG, Sreenman JM, Roche JF: The effect of dose and route of oestradiol benzoate administration on plasma concentrations of oestradiol and FSH in long-term ovariectomised heifers. Anim Reprod Sci 2000, 59:1-12.
21. Diskin MG, Austin EJ, Roche JF: Exogenous hormonal manipulation of ovarian activity in cattle. Domest Anim Endocrinol 2002, 23:211-228, (review).
22. O’Dohoo MJ, Novoa C, Vera WK, Davales: Ovarian follicle regression and emergence of new follicular wave after injection of 17β-oestradiol in alpacas, Australian Society for Reproductive Biology 1997, 29:102.
23. Vaughan JL: Control of ovarian follicular growth in the alpaca (Lama pacos), PhD thesis Central Queensland University 2001.
24. Ratto MH, Singh J, Huanca W, Adams GP: Ovarian follicular wave synchronization and pregnancy rate after fixed-time natural mating in llamas. Theriogenology 2003, 60:1645-1656.
25. Skidmore JA, Adams GP, Bilia M: Synchronisation of ovarian follicular waves in the dromedary camel (Camelus dromedarius). Anim Reprod Sci 2009, 114:249-255.
26. Oukessou M: Kinetic disposition of flunixin meglumine in the camel (Camelus dromedarius). Vet Res 1994, 25:71-79.
27. Ali BH, Oukessou M, Bashir AK, Mapletoft RJ: Pharmacokinetics considerations in the camel (Camelus dromedarius). Comp Biochem Physiol 1996, 115:1-9.
28. Navarre CB, Ravis WR, Nagila R, Deshmukh D, Simpkins A, Duran SH, Pugh DG: Pharmacokinetics of flunixin meglumine in llamas following single intravenous and oral doses. J Vet Pharmacol Ther 2001, 24:361-364.
29. Navarre CB, Ravis WR, Nagila R, Simpkins A, Duran SH, Pugh DG: Pharmacokinetics of phenylbutazone in llamas following single intravenous and oral doses. J Vet Pharmacol Ther 2001, 24:227-231.
30. Cancino AK: Control exógeno de la dinámica folicular ovárica y respuesta superovulatoria en llamas (Lama glama) con y sin cría al pie. (Exogenous control of follicular dynamics and superovulatory response in lactating and non lactating llamas (Lama glama). Master of Science thesis Facultad de Cs. Agrarias, Universidad Nacional de Mar del Plata. Balcarce, Argentina 2005, 150.
31. Aba MA, Quiroga MA, Auzá N, Forsberg M, Kindahl H: Control of ovarian activity in llamas (Lama glama) with medroxyprogesterone acetate. Reprod Domest Anim 1999, 34:471-476.
32. Siores J, Fortune JE: Lengthening the bovine estrous cycle with low levels of exogenous progesterone: a model for studying ovarian follicular dominance. Endocrinology 1990, 129:916-925.
33. Bianchi CP, Meikle A, Sartore I, González F, Aba MA: Uterine estrogen receptor alpha and progesterone receptor during the follicular and luteal phase in llamas. Anim Reprod Sci 2007, 99:117-126.
34. Vynckier P, Debackere M, De Kruif A, Coryn M: Plasma estradiol-17β concentrations in the cow during induced estrus and after injection of estradiol-17β benzoate and estradiol-17β cypionate—a preliminary study. J Vet Pharmacol Ther 1990, 13:36-42.
35. Baggot J: Pharmacokinetics: disposition and fate of drugs in the body. Veterinary Pharmacology and Therapeutics Ames Iowa 50014, USA: Iowa State University Press/Adams R 1995, 18-52.
36. Aba MA: Hormonal interrelationships in reproduction of female llamas and alpacas. PhD thesis Swedish University of Agricultural Sciences, Acta Univ. Agricult. Sueciae Vet 1998, (in press).
37. Chaves MG, Aba M, Agüero A, Egey J, Berestin V, Rutter B: Ovarian follicular wave pattern and the effect of exogenous progesterone on follicular activity in non-mated llamas. Anim Reprod Sci 2002, 69:331-347.
38. Aba MA: Studies on the reproductive endocrinology of llamas and alpacas from mating throughout early pregnancy. Master of Science thesis Swedish University of Agricultural Sciences, Upsalla 1995, 11-78.
39. Mapletoft RJ, Colazo MG, Martinez MF, Kastelic JP: Esteros de estrógeno para la sincronización de la emergencia de la onda follicular y la ovulación en animales tratados con dispositivos con progesterona. (Estradiol esters for synchronization of follicular wave emergence and ovulation in animals treated with progesterone releasing intravaginal devices), Proceedings of the V International Symposium of Animal Reproduction, RAC: 27-29 June Córdoba, Argentina 2003, 55-67.